A

Amvuttra

Product

by Alnylam Pharmaceuticals

Heard in 3 episodes across 2 shows since Oct 2026

Amvuttra is a prescription medicine developed by Alnylam Pharmaceuticals for treating transthyretin-mediated amyloidosis, including cardiomyopathy associated with ATTR-CM.

Discussed inMarkets100%

Episodes

3
across 2 shows

This week

0
episodes on 0 shows

Expert statements

3
1 positive · 2 negative

Share of the conversation

Mentions of Amvuttra per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.02‰0.04‰0.06‰Aug 24Sep 15Oct 8Oct 30Nov 21
Show the data
DayShare (7-day)Mentions
Oct 300.01‰1
Nov 130.03‰4

The full trend: rank, tone and why it is trending →

Email alert

Email me when Amvuttra comes up on a podcast

One email a week at most, with the new episodes that mention Amvuttra. Free, no account needed, unsubscribe in one click.

What experts have said about Amvuttra

3 statements · 1 positive · 2 negative

  1. Elaine ChenNegativeNov 13, 2026· The Readout Loud

    Alnylam is struggling to increase Amvuttra prescriptions

    “Alnylam is struggling with getting more prescriptions.”

    Listen at 8:09

    Open the episode · 421: The future of heart drug research in the wake of study setbacks
  2. Adam FeuersteinPositiveNov 13, 2026· The Readout Loud

    Amvuttra is a blockbuster drug

    “Amputra is a blockbuster drug.”

    Listen at 8:14

    Open the episode · 421: The future of heart drug research in the wake of study setbacks
  3. Paul MatteisNegativeNov 13, 2026· Biotech Hangout

    Alnylam’s Amvuttra launch has slowed below expectations.

    “The Almalum launch with Ambutra has kind of petered out”

    Listen at 27:11

    Open the episode · Episode 203 - November 13, 2026

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

3 episodes featuring Amvuttra, newest first